Premium
A unique vaccine for control of fertility and therapy of advanced‐stage terminal cancers ectopically expressing human chorionic gonadotropin
Author(s) -
Talwar G. P.
Publication year - 2013
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2012.06776.x
Subject(s) - human chorionic gonadotropin , ovulation , pregnancy , fertility , gonadotropin , andrology , medicine , embryo , human fertilization , biology , gynecology , hormone , population , microbiology and biotechnology , genetics , environmental health
Human chorionic gonadotropin (hCG) appears soon after fertilization of the egg and plays a critical role in implantation of the embryo leading to the beginning of pregnancy. Vaccines developed against hCG prevent pregnancy without impairment of ovulation and disturbance of menstrual regularity. A new recombinant vaccine hCGβ‐LTB has been developed that is highly immunogenic in various strains of mice and intended for the control of fertility in women. An additional use of this vaccine is likely to be treatment of advanced‐stage cancers that ectopically express hCG.